Peptron, Inc.

Equities

A087010

KR7087010005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 04/06/2024 am IST			5-day change	1st Jan Change
39,800 ^KRW	+6.85%		+8.15%	-1.12%

2023	Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	MT
2023	Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

UNO&COMPANY Ltd. acquired 3.66% stake in Peptron, Inc. for approximately KRW 1 billion.

February 10, 2014 at 09:30 am IST

UNO&COMPANY Ltd. (KOSDAQ:A114630) acquired 3.66% stake in Peptron, Inc. for approximately KRW 1 billion on February 10, 2014. UNO&COMPANY acquired 0.15 million shares of Peptron.

UNO&COMPANY Ltd. (KOSDAQ:A114630) completed the acquisition of 3.66% stake in Peptron, Inc. on February 10, 2014.

Latest news about Peptron, Inc.

Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	22/12	MT
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	04/23/04	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	04/23/04	CI
Peptron, Inc.'s Equity Buyback announced on April 5, 2023, has expired with 73,961 shares, representing 0.36% for KRW 891.08 million.	04/23/04	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	07/23/07	CI
Peptron, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	05/23/05	CI
Peptron, Inc. authorizes a Buyback Plan.	05/23/05	CI
Peptron, Inc. Establishes Bioequivalence of PT105	28/22/28	CI
Invex Therapeutics Ltd Announces the Signing of a Long Term Collaboration and Manufacturing Agreement with Peptron, Inc	27/21/27	CI
Qilu Pharmaceutical and Peptron Sign License Agreement for Anti-MUC1 ADC	16/21/16	CI
Peptron, Inc. Announces Published Data Showing a New Sustained-Release Exendin-4 Formulation Prevents Neurodegeneration in a Parkinson's Disease Model	16/18/16	CI
Peptron, Inc. announced that it has received $24 million in funding	23/18/23	CI
Peptron, Inc. announced that it has received KRW 25.5 billion in funding from Industrial Bank of Korea	31/18/31	CI
Peptron, Inc. announced that it expects to receive KRW 25.5 billion in funding from Industrial Bank of Korea	29/18/29	CI
Peptron, Inc. announced that it has received funding from E&Investment,Inc.	25/16/25	CI
Peptron, Inc. announced that it has received KRW 2 billion in funding from UNO & COMPANY Ltd.	25/16/25	CI
Peptron, Inc. announced that it expects to receive KRW 2 billion in funding from UNO & COMPANY Ltd.	20/16/20	CI
Peptron, Inc.(KOSDAQ:A087010) added to Russell Global Index	01/15/01	CI
Peptron, Inc.(KOSDAQ:A087010) added to S&P Global BMI Index	21/15/21	CI
Peptron, Inc. has completed an IPO in the amount of KRW 13.04 billion.	17/15/17	CI
Peptron, Inc. has filed an IPO.	04/14/04	CI
UNO&COMPANY Ltd. acquired 3.66% stake in Peptron, Inc. for approximately KRW 1 billion.	10/14/10	CI

Chart Peptron, Inc.

Duration

Period

More charts

Company Profile

Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTRON, INC.	-1.12%	60Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	12TCr
REGENERON PHARMACEUTICALS, INC.	+13.04%	11TCr
BIONTECH SE	-5.80%	2.4TCr
ARGENX SE	+2.07%	2.26TCr
GENMAB A/S	-10.09%	1.82TCr
WUXI APPTEC CO., LTD.	-40.52%	1.68TCr
BEIGENE, LTD.	-14.00%	1.62TCr
NEUROCRINE BIOSCIENCES, INC.	+1.18%	1.34TCr
SAREPTA THERAPEUTICS, INC.	+24.18%	1.13TCr

Bio Therapeutic Drugs